MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a single-blind Phase...

MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a Phase III...

Eye disease company Surface Pharmaceuticals Inc. (Pleasanton, Calif.) launched with a $20 million series A round funded by an investment entity managed by Flying L Partners. Surface is a spinout from drug delivery company and...

Eye disease company Surface Pharmaceuticals Inc. (Pleasanton, Calif.) launched with a $20 million series A round funded by an investment entity managed by Flying L Partners. Surface is a spinout from drug delivery company and...

Leo said Enstilar calcipotriene/betamethasone received a positive outcome under EU’s decentralized procedure to treat plaque psoriasis in adults. Leo expects national approvals this year. The aerosol foam formulation of a fixed-dose combination of 0.005% calcipotriene,...

Psoriasis patients have told FDA they need relief from more symptoms than the visible skin lesions that often serve as the primary endpoint of registrational trials. The need is not lost on drug developers, which...

The double-blind, placebo-controlled, U.S. Phase III PSO-FAST trial in 426 patients with psoriasis vulgaris showed that Enstilar improved itch in 37% of patients after 3 days and in 84% of patients by week 4. Additionally,...